Canada Pension Plan Investment Board Makes New $156,000 Investment in RxSight, Inc. (NASDAQ:RXST)

Canada Pension Plan Investment Board acquired a new stake in shares of RxSight, Inc. (NASDAQ:RXST) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,600 shares of the company’s stock, valued at approximately $156,000.

Several other institutional investors also recently made changes to their positions in RXST. CWM LLC grew its stake in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after buying an additional 371 shares during the period. Quest Partners LLC purchased a new stake in shares of RxSight during the 2nd quarter valued at $41,000. Larson Financial Group LLC purchased a new stake in shares of RxSight during the 1st quarter valued at $51,000. Amalgamated Bank grew its stake in shares of RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after buying an additional 207 shares during the period. Finally, RiverPark Advisors LLC grew its stake in shares of RxSight by 361.4% during the 1st quarter. RiverPark Advisors LLC now owns 3,082 shares of the company’s stock valued at $159,000 after buying an additional 2,414 shares during the period. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on RXST. Wells Fargo & Company lowered their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of RxSight in a report on Friday, September 13th. BTIG Research lifted their target price on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, July 15th. Oppenheimer reduced their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Finally, Stifel Nicolaus reduced their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $60.14.

Insiders Place Their Bets

In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $58.61, for a total value of $586,100.00. Following the transaction, the chief financial officer now owns 13,938 shares in the company, valued at approximately $816,906.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $53.19, for a total value of $164,889.00. Following the completion of the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $2,247,064.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Shelley B. Thunen sold 10,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at approximately $816,906.18. The disclosure for this sale can be found here. Insiders have sold 25,200 shares of company stock worth $1,267,516 in the last quarter. 9.36% of the stock is owned by corporate insiders.

RxSight Price Performance

Shares of RXST stock opened at $48.54 on Friday. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54. The firm has a market capitalization of $1.80 billion, a P/E ratio of -38.52 and a beta of 1.22. The company’s fifty day moving average price is $51.15 and its two-hundred day moving average price is $53.84.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same quarter in the previous year, the business posted ($0.40) EPS. The firm’s revenue was up 67.6% compared to the same quarter last year. On average, sell-side analysts anticipate that RxSight, Inc. will post -0.81 EPS for the current year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.